Prostate cancer

The following highlights relevant clinical data on prostate cancer:

• 89% of individuals with prostate cancer do not have a positive family history of the disease¹
• 58% of prostate cancer risk is environmental -- diet, weight, smoking, etc.²
• First PSA is rarely done before age 50 and detects disease after it is present

Why Navigenics?

With Navigenics PC genotyping you have the potential to identify the 20% of people whose estimated average PC risk is 50% greater than the population’s risk³

Clinical Relevance

	PSA Measurement	Navigenics Genotyping: Prostate Cancer
Focus of test	Diagnosis	Prevention
Timing	After age 50	Any age*
Frequency	Every year - velocity matters	Generally a one-time saliva collection

*Navigenics currently tests adults 18 years or older

The same test covers 26 other conditions, providing you with genetic risk information that informs clinical decision-making and preventative guidance.

Why now? 

A recent NEJM study indicates that PC is more strongly associated with a high composite genetic risk score for PC than with family history, age, or PSA level at time of diagnosis.⁴

Get the jump on chronic disease by incorporating personal genetic risk today.

1. NCI CGEMS Prostate Cancer data set: http://cgems.cancer.gov/data/, Yeager. Nat Genet 39:645. 2007
2. Lichtenstein. N Engl J Med 343:78. 2000
3. Based on Navigenics composite genetic risk calculations using a HapMap reference population. For more information on these calculations, including our mathematical models and curation practices, please see “The Science Behind the Navigenics Service,” a white paper found at http://www.navigenics.com/static/pdf/Navigenics-TheScience.pdf.
4. Zheng. N Engl J Med 358:9. 2008